A Double Blind Short-Term Presurgical Study Assessing the Molecular Antiproliferative Predictors of Lapatinib's Effects in Breast Cancer
Randomised multi centre double blind pre-surgical study in women with a histological
diagnosis of breast cancer by core biopsy.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Changes in Ki67 after short term treatment with lapatinib.
Paired core samples taken at baseline and time of main surgery analysed for Ki67, TUNEL, HER2, EGFR, ER, PgR, pAkt,pERK & stathmin
11-14 days after treatment
No
Professor Ian Smith
Principal Investigator
Royal Marsden NHS Foundation Trust
United Kingdom: Medicines and Healthcare Products Regulatory Agency
CCR2737
NCT00299286
June 2007
August 2011
Name | Location |
---|